741 related articles for article (PubMed ID: 26109209)
1. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
4. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
[TBL] [Abstract][Full Text] [Related]
7. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Tsagkataki M; Papathomas T; Lythgoe D; Kamal A
Semin Ophthalmol; 2015; 30(5-6):352-9. PubMed ID: 24875368
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
12. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion.
Ahmadi AA; Chuo JY; Banashkevich A; Ma PE; Maberley DA
Can J Ophthalmol; 2009 Apr; 44(2):154-9. PubMed ID: 19491948
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.
Khan M; Wai KM; Silva FQ; Srivastava S; Ehlers JP; Rachitskaya A; Babiuch A; Deasy R; Kaiser PK; Schachat AP; Yuan A; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2017 Jun; 48(6):465-472. PubMed ID: 28613352
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.
Tomomatsu Y; Tomomatsu T; Takamura Y; Gozawa M; Arimura S; Takihara Y; Inatani M
Acta Ophthalmol; 2016 May; 94(3):e225-30. PubMed ID: 25989706
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
17. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]